drugset
drugset / Trial / NCT04503603

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

NCT04503603 ↗

Phase 1 Completed 12 enrolled Takeda Takeda Development Center Americas, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study to evaluate the safety, tolerability and pharmacokinetics (PK) of lanadelumab administered by Intravenous (IV) infusion in healthy adult volunteers.

Timeline

Start
2020-08-10
Primary completion
2020-12-23
Completion
2020-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanadelumab Monoclonal antibody 300 mg Intravenous

Indications

No indication recorded.